Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs VYGR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RGNX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

RGNX Overall Winner 6-Pillar Tally: RGNX 4 – 2 VYGR Matrix Metrics: RGNX 5 – 5 VYGR

As of Nov 16, 2026, REGENXBIO Inc. (RGNX) is the stronger overall head-to-head candidate over Voyager Therapeutics, Inc. (VYGR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas VYGR carries 46.3/100 (HOLD) at $1.67 (8.4x Forward P/E, -436.2% operating margin).

  • Composite vs. Pillar Nuance: While VYGR currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. RGNX 45.3/100 HOLD), RGNX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-120.4% vs. -436.2% operating margin) and revenue trajectory (-69.2% vs. -70.0% YoY).
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile VYGR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs VYGR
RGNX NASDAQ Head-to-Head Winner
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
VYGR NASDAQ
Voyager Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.67
-3.76% 1D
Market Cap $102.7M
TTM Revenue $25M
Forward P/E 8.4x
Beta / 30D Vol 1.43β · 85% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 40.0 Fund 62.0 Flow 64.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.9%), weak momentum, RSI 37
RSI-14: 36.8 · SMA20: $1.82 · SMA50: $2.34

6-Pillar Scorecard Institutional Category Breakdown (RGNX 4 – 2 VYGR)

Columns: Metric · RGNX · VYGR
1. Valuation Multiples VYGR
Forward P/E N/M 8.4x
Trailing P/E N/M 8.4x
PEG Ratio 0.26x N/M
EV / Revenue 3.1x 3.4x
2. Growth & Scale RGNX
Revenue Growth (YoY) -69.2% -70.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M $25M
Market Cap $500.9M $102.7M
3. Profitability & Quality RGNX
Gross Margin -64.5% N/A
Operating Margin -120.4% -436.2%
Net Profit Margin -113.9% 0.0%
Return on Equity (ROE) -113.2% -58.9%
4. Balance Sheet & Cash Flow VYGR
Cash Generation (TTM) -$155M -$110M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $18M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 349.6% (52nd %ile) 130.1% (31st %ile)
Put/Call OI Skew N/A 2.35x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (5) vs VYGR (5)
Institutional Metric RGNX VYGR Criterion Row Edge
Market Capitalization
Scale
$500.9M $102.7M Larger Scale RGNX
Trailing P/E Ratio
Valuation
N/M 8.4x Lower Multiple VYGR
Forward P/E Ratio
Valuation
N/M 8.4x Lower Multiple VYGR
Revenue Growth (YoY)
Growth
-69.2% -70.0% Higher Growth RGNX
Operating Margin (TTM)
Profitability
-120.4% -436.2% Higher Margin RGNX
Net Profit Margin
Profitability
-113.9% 0.0% Higher Margin VYGR
Return on Equity (ROE)
Capital Efficiency
-113.2% -58.9% Higher ROE VYGR
52-Week Range Position
Momentum
19% ($5–$16) 2% ($2–$5) Stronger Trend RGNX
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 1.43β · 85% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite VYGR
Trailing 12M Revenue (USD)
Operating Scale
$154M $25M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · 3.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$110M ($18M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +20.24 pp
RGNX: +7.87% · VYGR: -12.37%
3M Horizon RGNX +17.03 pp
RGNX: -32.52% · VYGR: -49.55%
6M Horizon RGNX +85.04 pp
RGNX: +32.21% · VYGR: -52.83%
1Y Horizon RGNX +22.35 pp
RGNX: -35.82% · VYGR: -58.17%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue VYGR Revenue RGNX Op. Margin VYGR Op. Margin Margin Leader
FY2018 $220M $10M 40.3% -1195.6% RGNX
FY2019 $40M $100M -422.9% -49.5% VYGR
FY2020 $150M $170M -77.1% 16.0% VYGR
FY2021 $470M $40M 34.0% -196.8% RGNX
FY2022 $110M $40M -233.2% -124.3% VYGR
FY2023 $90M $250M -297.1% 48.8% VYGR
FY2024 $80M $80M -280.0% -104.1% VYGR
FY2025 $170M $40M -94.6% -326.6% RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VYGR BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 130.1%
IV Percentile 31st %ile
Put/Call OI Skew 2.35x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VYGR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
VYGR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $102.7M market capitalization and -436.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs VYGR Key Questions & Quantitative Answers

As of Nov 16, 2026, REGENXBIO Inc. (RGNX) is the stronger overall head-to-head candidate over Voyager Therapeutics, Inc. (VYGR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas VYGR carries 46.3/100 (HOLD) at $1.67 (8.4x Forward P/E, -436.2% operating margin). Composite vs. Pillar Nuance: While VYGR currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. RGNX 45.3/100 HOLD), RGNX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-120.4% vs. -436.2% operating margin) and revenue trajectory (-69.2% vs. -70.0% YoY). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile VYGR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RGNX leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with VYGR at -70.0% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -436.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while VYGR shifted +300.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VYGR.

VYGR screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas VYGR trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 3.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus VYGR (-58.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, VYGR carries 130.1% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 2.35x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.43β · 85% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.